CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Roy, Ishan ^a   Zimmerman, Noah P ^a   Mackinnon, A Craig ^a   Tsai, Susan ^a   Evans, Douglas B ^a   Dwinell, Michael B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; STROMAL CELL DERIVED FACTOR 1; TUMOR SUPPRESSOR PROTEIN; CHEMOKINE RECEPTOR CXCR; CXCL12 PROTEIN, HUMAN; CXCR7 PROTEIN, HUMAN; LIGAND;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; ANOIKIS; CELL ADHESION; CELL PROLIFERATION; CHEMOTAXIS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EPITHELIUM; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; SCID MOUSE; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANOIKIS; CARCINOMA, PANCREATIC DUCTAL; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; CHEMOTAXIS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MICE, SCID; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTORS, CXCR; RECEPTORS, CXCR4; SURVIVAL ANALYSIS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897093538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090400     Document Type: Article

References (63)

1. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. (2008) Pancreatic carcinogenesis. Pancreatology 8: 110-125. (Pubitemid 351670364)
2. Maitra A, Hruban RH. (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188. (Pubitemid 351488279)
3. Hidalgo M. (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617.
4. Haeno H, Gonen M, Davis M, Herman J, Iacobuzio-Donahue C, et al. (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148: 362-375.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
6. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. (Pubitemid 40719130)
7. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, et al. (2006) Hedgehog/ras interactions regulate early stages of pancreatic cancer. Genes & Development 20: 3161-3173. (Pubitemid 44790630)
8. Abul K. Abbas, Andrew H. Lichtman. (2010) Basic immunology: Functions and disorders of the immune system. : Saunders/Elsevier, 2010. 312 pages p.
9. Raman D, Baugher PJ, Thu YM, Richmond A. (2007) Role of chemokines in tumor growth. Cancer Lett 256: 137-165. (Pubitemid 47418345)
10. Teicher BA, Fricker SP. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931.
11. Heidemann J, Ogawa H, Rafiee P, Lugering N, Maaser C, et al. (2004) Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 286: G1059-68. (Pubitemid 38715670)
12. Dwinell MB, Ogawa H, Barrett KE, Kagnoff MF. (2004) SDF-1/CXCL12 regulates cAMP production and ion transport in intestinal epithelial cells via CXCR4. Am J Physiol Gastrointest Liver Physiol 286: G844-50. (Pubitemid 38506817)
13. Smith JM, Johanesen PA, Wendt MK, Binion DG, Dwinell MB. (2005) CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity. Am J Physiol Gastrointest Liver Physiol 288: G316-26. (Pubitemid 40129584)
14. Zimmerman NP, Vongsa RA, Faherty SL, Salzman NH, Dwinell MB. (2011) Targeted intestinal epithelial deletion of the chemokine receptor CXCR4 reveals important roles for extracellular-regulated kinase-1/2 in restitution. Lab Invest 91: 1040-1055.
15. Dwinell MB, Johanesen PA, Smith JM. (2003) Immunobiology of epithelial chemokines in the intestinal mucosa. Surgery 133: 601-607. (Pubitemid 36688312)
16. Hwang S, Zimmerman NP, Agle KA, Turner JR, Kumar SN, et al. (2012) E-cadherin is critical for collective sheet migration and is regulated by the chemokine CXCL12 protein during restitution. Journal of Biological Chemistry 287: 22227-22240.
17. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56. (Pubitemid 32225831)
18. Arya M, Patel HRH, Williamson M. (2003) Chemokines: Key players in cancer. Curr Med Res Opin 19: 557-564. (Pubitemid 37122049)
19. Zlotnik A. (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14: 181-185.
20. Zlotnik A. (2006) Chemokines and cancer. Int J Cancer 119: 2026-2029.
21. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, et al. (2007) Expression of growth factor and chemokine receptors: New insights in the biology of inflammatory breast cancer. Ann Oncol 18: 1021-1029. (Pubitemid 47050493)
22. Zlotnik A. (2008) New insights on the role of CXCR4 in cancer metastasis. J Pathol 215: 211-213.
23. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Research 63: 3833-3839. (Pubitemid 36793074)
24. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, et al. (2006) Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 25: 4986-4997.
25. Wendt MK, Cooper AN, Dwinell MB. (2008) Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 27: 1461-1471. (Pubitemid 351317456)
26. Wendt MK, Drury LJ, Vongsa RA, Dwinell MB. (2008) Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells. Gastroenterology 135: 508-517.
27. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, et al. (2009) The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 175: 66-73.
28. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, et al. (2010) Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29: 5159-5170.
29. Clatot F, Picquenot J, Choussy O, Gouérant S, Moldovan C, et al. (2011) Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 47: 1062-1068.
30. Zhi Y, Chen J, Zhang S, Chang X, Ma J, et al. (2012) Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci 57: 650-659.
31. Baumhoer D, Smida J, Zillmer S, Rosemann M, Atkinson MJ, et al. (2012) Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol 25: 522-528.
32. Ramos E, Camargo A, Braun K, Slowik R, Cavalli I, et al. (2010) Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer 10: 23.
33. Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, et al. (2010) Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 123: 733-745.
34. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, et al. (2009) CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 45: 2579-2587.
35. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, et al. (2010) High levels of expression of human stromal Cell-Derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiology Biomarkers & Prevention 19: 2598-2604.
36. Zhong W, Chen W, Zhang D, Sun J, Li Y, et al. (2012) CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med 4: 363-369.
37. Zlotnik A. (2006) Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol 13: 191-199.
38. Burger JA, Kipps TJ. (2006) CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767. (Pubitemid 43289351)
39. Cui K, Zhao W, Wang C, Wang A, Zhang B, et al. (2010) The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Surg Res.
40. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, et al. (2004) Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64: 8420-8427. (Pubitemid 39491782)
41. Billadeau DD, Chatterjee S, Bramati P, Sreekumar R, Shah V, et al. (2006) Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer 37: 110-119. (Pubitemid 351642211)
42. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, et al. (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 6: 3530-3535.
43. Drury LJ, Wendt MK, Dwinell MB. (2010) CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through bim-mediated intrinsic apoptosis. PLoS One 5: e12895.
44. Adams EJ, Green JA, Clark AH, Youngson JH. (1999) Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 52: 75-77. (Pubitemid 29023513)
45. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, et al. (2011) Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A 108: 17655-17660.
46. Spicer JD, McDonald B, Cools-Lartigue JJ, Chow SC, Giannias B, et al. (2012) Neutrophils promote liver metastasis via mac-1-Mediated interactions with circulating tumor cells. Cancer Research 72: 3919-3927.
47. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, et al. (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4: 1670-1680.
48. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. (2001) Molecular pathology of pancreatic cancer. Cancer J 7: 251-258.
49. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, et al. (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28: 977-987. (Pubitemid 38971421)
50. Hruban RH, Wilentz RE, Maitra A. (2005) Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med 103: 1-13.
51. Maitra A, Fukushima N, Takaori K, Hruban RH. (2005) Precursors to invasive pancreatic cancer. Adv Anat Pathol 12: 81-91. (Pubitemid 40515796)
52. Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, et al. (2008) Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 206: 833-846.
53. Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, et al. (2012) Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. Journal of Gastrointestinal Surgery 16: 784-792.
54. Gillen S, Schuster T, Meyer zB, Friess H, Kleeff J. (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and metaanalysis of response and resection percentages. PLoS Med 7: e1000267.
55. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF. (2005) The monomerdimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 14: 1071-1081. (Pubitemid 40389378)
56. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, et al. (2011) Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A 108: 17655-17660.
57. Siegel R, Naishadham D, Jemal A. (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29.
58. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, et al. (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 28: 495-500.
59. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393: 591-594. (Pubitemid 28319250)
60. Zou Y, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393: 595-599. (Pubitemid 28319251)
61. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213. (Pubitemid 44352240)
62. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382: 635-638. (Pubitemid 26268957)
63. Veldkamp CT, Ziarek JJ, Su J, Basnet H, Lennertz R, et al. (2009) Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci 18: 1359-1369.